| Identification | |
| Name: | Piperazine,1-[(4-chlorophenyl)phenylmethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]- |
| Synonyms: | Piperazine,1-(p-tert-butylbenzyl)-4-(p-chloro-a-phenylbenzyl)- (6CI,7CI,8CI); 1-(p-Chloro-a-phenylbenzyl)-4-(p-tert-butylbenzyl)piperazine;1-(p-Chlorobenzhydryl)-4-(p-tert-butylbenzyl)-diethylenediamine;1-(p-Chlorobenzhydryl)-4-(p-tert-butylbenzyl)-piperazine;1-(p-tert-Butylbenzyl)-4-(p-chloro-a-phenylbenzyl)piperazine; AH 2526; Aphilan R base; Buclifen; Buclizine;Histabuticine; Histabutizine; Histabutyzine; Hitabutyzyne; Posdel; Postafen |
| CAS: | 82-95-1 |
| EINECS: | 201-448-1 |
| Molecular Formula: | C28H33 Cl N2 |
| Molecular Weight: | 433.08 |
| InChI: | InChI=1S/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1-3H3 |
| Molecular Structure: |  |
| Properties | |
| Specification: |
Buclizine (CAS NO.82-95-1) is an antihistamine of the piperazine derivative family. It is considered to be an antiemetic, similar to meclizine. Buclizine is categorized under the following by the FDA: Antiemetics ; Antihistamine ; Anticholinergic ; ATC:R06AE01 |
| Safety Data | |
 |
|
